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Abstract
Introduction: Severe fatigue is a major health problem in fibromyalgia (FM). Obesity is common in FM, but the
influence of adipokines and growth factors is not clear. The aim was to examine effects of exercise on fatigue, in
lean, overweight and obese FM patients.
Methods: In a longitudinal study, 48 FM patients (median 52 years) exercised for 15 weeks. Nine patients were
lean (body mass index, BMI 18.5 to 24.9), 26 overweight (BMI 25 to 29.9) and 13 obese. Fatigue was rated on a 0
to 100 mm scale (fibromyalgia impact questionnaire [FIQ] fatigue) and multidimensional fatigue inventory (MFI-20)
general fatigue (MFIGF). Higher levels in FIQ fatigue and MFIGF indicate greater degree of fatigue. Free and total
IGF-1, neuropeptides, adipokines were determined in serum and cerebrospinal fluid (CSF).
Results: Baseline FIQ fatigue correlated negatively with serum leptin (r = -0.345; P = 0.016) and nerve growth factor
(NGF; r = -0.412; P = 0.037). In lean patients, baseline MFIGF associated negatively with serum resistin (r = -0.694;
P = 0.038). FIQ Fatigue associated negatively with CSF resistin (r = -0.365; P = 0.073). Similarly, FIQ fatigue (r = -0.444;
P = 0.026) and MFIGF correlated negatively with CSF adiponectin (r = -0.508; P = 0.01). In lean patients, FIQ fatigue
(P = 0.046) decreased after 15 weeks. After 30 weeks, MFIGF decreased significantly in lean (MFIGF: P = 0.017),
overweight (MFIGF: P = 0.001), and obese patients (MFIGF: P = 0.016). After 15 weeks, total IGF-1 increased in lean
(P = 0.043) patients. ΔTotal IGF-1 differed significantly between lean and obese patients (P = 0.010). ΔTotal IGF-1
related negatively with ΔMFIGF after 15 weeks (r = -0.329; P = 0.050). After 30 weeks, ΔFIQ fatigue negatively
correlated with ΔNGF (r = -0.463; P = 0.034) and positively with Δneuropeptide Y (NPY) (r = 0.469; P = 0.032). Resistin
increased after 30 weeks (P = 0.034). ΔMFIGF correlated negatively with Δresistin (r = -0.346; P = 0.031), being
strongest in obese patients (r = -0.815; P = 0.007). In obese patients, ΔFIQ fatigue after 30 weeks correlated negatively
with Δfree IGF-1 (r = -0.711; P = 0.032).
Conclusions: Exercise reduced fatigue in all FM patients, this effect was achieved earlier in lean patients. Baseline
levels of resistin in both serum and CSF associated negatively with fatigue. Resistin was increased after the exercise
period which correlated with decreased fatigue. Changes in IGF-1 indicate similar long-term effects in obese
patients. This study shows reduced fatigue after moderate exercise in FM and indicates the involvement of IGF-1
and resistin in these beneficial effects.
Trial registration: ClinicalTrials.gov: NCT00643006
Introduction
Severe fatigue, together with pain, is a major health
problem in fibromyalgia (FM) [1,2] and is considered to
be equally important to pain [3] in causing impaired
work ability and restricted social participation [4]. It is
associated with depression, sleep quality and pain [5].
Obesity is common in FM, with a reported prevalence
between 40 and 70% [6-8]. Increased body mass index
(BMI) generally correlates with increased levels of pain
and fatigue in FM [7,9-11]. In chronic fatigue syndrome,
symptom severity is suggested to be associated with
metabolic syndrome [12]. Weight levels may affect
neuroendocrine regulation of pain and fatigue through
several pathways.
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There is evidence for deregulation of the growth
hormone/insulin-like growth factor (IGF-1) signaling in
obesity [13,14] and an inverse relationship between total
IGF-1 levels and BMI has been reported [15,16]. In FM
patients we have recently reported a beneficial role of
IGF-1 and exercise with regard to pain [17]. These
results were in line with previous findings indicating
that IGF-1 has a protective role in FM [18,19] and that
IGF-1 promotes resilience to stress and pain in the cen-
tral nervous system (CNS) [20,21]. Furthermore, growth
hormone deficiency is shown to be associated with fati-
gue and reduced cognitive speed [22].
Recently, several factors, termed adipokines, which are
produced in adipose tissue, have been found to have
important regulatory roles in both inflammation and
nutrition. Adiponectin is one of these adipokines and
was initially isolated in adipocytes. Adiponectin regulates
energy balance both in peripheral tissues and via the
CNS [23,24]. Adiponectin receptors are distributed
widely in the brain, affecting appetite, metabolism and
autonomic function [25,26]. Adiponectin is negatively
correlated with depression [27,28] and has antidepres-
sant-like effects in both lean and diet-induced obese
mice [29].
Resistin is considered to be an adipokine with unusual
properties, and a potential link between inflammation
and metabolic disease [30]. It is expressed in human
macrophages and has documented regulatory effects on
metabolism, adipogenesis and inflammatory reactions
[31-33]. Peripheral levels of resistin are upregulated in
subjects with insulin resistance and in obesity [34,35],
and resistin signaling involves both toll-like receptor
(TLR)4 [36] and the IGF-1 receptor [37].
Leptin is another important adipokine. It is a major
product of adipose tissue, is increased in obesity and is
a central regulator of satiety and body weight [38,39], as
well as reproduction, mood and emotion [40-42]. Induc-
tion of satiety is mediated by leptin receptors in
hypothalamic neuropeptide Y (NPY), producing neurons
[43-46]. Leptin has anxiolytic effects in mice [47,48] and
is involved in allodynia in a neuropathic pain model
[49]. NPY is an abundant neuropeptide, both in the per-
ipheral and in the central nervous system. NPY is an
important modulator of hippocampal and thalamic
circuits, with the potential to affect a number of differ-
ent functions in the brain. It is also involved in neuro-
protection, neurogenesis and neuroinflammation [50].
NPY is altered in FM patients, possibly involving the
hypothalamic-pituitary-adrenal axis [51-54]. NPY is also
altered in chronic fatigue syndrome [55,56] and during
stress and depression [57]. Disturbed neuropeptide
levels with elevated substance P (SP) [58-60] and nerve
growth factor (NGF) [61] have previously been found in
cerebrospinal fluid in FM. Recent evidence also impli-
cate glial activation in FM with increased IL-6 and IL-8
in cerebrospinal fluid [62].
The aim of the study was to examine the long-term
effects of aerobic exercise on fatigue, in lean, overweight,
and obese women with FM. Changes in serum free
bioactive IGF-1, total IGF-1, IGF binding protein
(IGFBP)3, adipokines and neuropeptides were studied to
gain a better understanding of the biological mechan-
isms involved in fatigue in FM.
Materials and methods
Study design
This study is a part of a previously reported randomized
controlled exercise study, studying the effects of a
moderate-to-high-intensity Nordic walking (NW) program
and a supervised low-intensity walking (LIW) program.
The effects of Nordic walking on body function were
reported previously [63], showing that NW resulted in bet-
ter improvement in the 6-minute walk test (6MWT) and
aerobic capacity, when compared with LIW.
Subjects
The criteria for inclusion were as follows: women with
FM, aged 20 to 60 years, with interest in exercising out-
doors twice a week for 15 weeks, who agreed to undergo
blood tests at baseline and after the exercise period. To
ensure that the patients would manage the planned
aerobic exercise, they were required to complete a
bicycle test at 50 watts to fulfill the inclusion criteria.
All included patients managed to perform the test. They
were also invited to participate in an examination of
cerebrospinal fluid; however, this was not a criterion for
inclusion. FM was defined by the American College
of Rheumatology (ACR) 1990 criteria [64]: a history of
long-lasting generalized pain and pain in at least 11 of
18 tender points examined by manual palpation.
The criteria for exclusion were as follows: patients
who could not speak or read Swedish; presence of other
severe somatic or psychiatric disease; BMI <18.5;
ongoing or planned physical therapy, including exercise,
and inability to attend at the times of the planned exer-
cise sessions.
Forty-nine patients, 26 of them undertaking NW and
23 undertaking LIW, had blood tests at baseline, after
15 weeks of exercise, and at 30 weeks of follow-up, as
described in the previous report [17]. One of the
patients had BMI <18.5 and was therefore excluded
from this study. In total, 48 patients with FM formed
the study population.
The median age of patients was 52 (48 to 56, inter-
quartile range) years and their median duration of
symptoms was 11 (7 to 15) years. The median number
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of tender points was 15 (13 to 16). Eighty-two percent
of patients were taking analgesics during the study and
63% were taking antidepressants or sedatives. Nine
patients were lean (BMI 18.5 to 24.9), 26 patients were
overweight (BMI 25.0 to 29.9) and 13 were obese (BMI
≥30.0). After separating the patients into BMI groups we
found a similar distribution in the NW and LIW group.
In the lean group, four subjects participated in NW and
five in LIW. In the overweight group fifteen participated
in NW and eleven in LIW. In the obese group seven
participated in NW and six in LIW.
Exercise intervention
The patients were randomized to either the moderate-
to-high-intensity NW program (n = 26) or the super-
vised LIW program (n = 22). Both supervised aerobic
exercise programs were conducted twice a week for 40
to 45 minutes for 15 weeks. Patients had blood tests
before, after 15 weeks, and after 30 weeks. Pain and
fatigue did not significantly change in any of the exer-
cise groups after 15 weeks, while scores in the Multidi-
mensional Fatigue Inventory (MFI-20) [66] subscale of
General Fatigue (MFIGF) improved in both groups after
30 weeks. As no differences in fatigue or pain were
found between the two exercise groups, and BMI was
similarly distributed in both exercise groups, the analyses
in this study were conducted on the total population
(n = 48), irrespective of exercise intensity. Compliance
was assessed as attendance at exercise sessions. It was
slightly higher among the lean group, whose attendance
was 71%, while it was 64% in the overweight group.
Attendance in the obese group was 57%.
Clinical measurements
Fatigue was rated on a visual analog scale (0 to 100) of
the Fibromyalgia Impact Questionnaire (FIQ) [65] which
gives an estimation of global fatigue, as well as with the
MFIGF [66], which estimates fatigue by questions
related to feeling fit, tired and rested. Both instruments
reflect fatigue during the last week, and a higher score
indicates more severe fatigue.
Blood and cerebrospinal fluid (CSF) sampling
Serum was collected at rest (n = 48) at baseline, after 15
weeks in the exercise program, and at 30 weeks of
follow-up (n = 41). Serum samples were acquired by
venipuncture of the cubital vein. Twenty-six patients
agreed to participate in an examination of cerebrospinal
fluid (CSF) at baseline. CSF was collected through lum-
bar puncture through the lumbar vertebrae (L)3/L4
interspace. Collected blood and CSF samples were cen-
trifuged at 800 g for 3 minutes, aliquoted, and stored
frozen at -70°C until use.
Laboratory analyses
Samples were analyzed with enzyme-linked immunosor-
bent assay (ELISA) using commercially available kits.
Assays specific for human adiponectin (DY1065,
62.5 pg/ml), human leptin (DY 398. 31 pg/ml), human
resistin (DY1359, 31 pg/ml), free bioactive IGF-1
(DY291, 4 pg/ml) and IGFBP3 (DY675, 0.125ng/ml)
were purchased from R and D Systems (Minneapolis,
MN, USA). Serum total IGF1 was measured by solid-
phase, enzyme-labeled chemoluminescent immunoassay
(Immulite 2000 IGF1, L2KGF2) on an Immulite 2000
(Siemens Medical Solutions Diagnostics, Los Angeles,
CA, USA). An assay specific for NPY (FEK-049-03,
1 pg/ml) was purchased from Phoenix Pharmaceuticals
(Burlingame, CA, USA). The human NGF-specific assay
was purchased from Promega (Madison, WI, USA;
4 pg/ml). All assays were run according to recommen-
dations of the manufacturers. Ordinary colorimetric
ELISA was read with a Spectramax 340 from Molecular
Devices (Sunnyvale, CA, USA), and fluorescent ELISA
assays were read with a Mithras LB940 from Berthold
Technologies (Bad Wildbad, Germany).
Statistics
Descriptive data are presented as median and interquar-
tile range. The Wilcoxon signed-rank test was used for
comparisons of continuous variables within groups.
Baseline data and differences in changes in lean patients
were compared by the Mann-Whitney U-test with over-
weight and obese patients, respectively. Relationships
between the variables were examined with the Spearman
correlation coefficient. To control for possible Type I
errors, the upper limit of the number of false significant
results was calculated by the following formula:
(
Number of tests − Number of significant tests on level of alpha) ∗Alpha/ (1-Alpha) .
Ethics
The study was approved by the ethics committee of
Sahlgrenska University Hospital. Written and verbal
information was given to all patients, and written con-
sent was obtained from all patients.
Results
Relationship between obesity, fatigue, adipokines and
IGF-1
Several differences in fatigue and adipokines were found
in relation to obesity. Patients with normal BMI (18.5 to
24.9) had higher baseline fatigue (97 mm) compared
to overweight patients with BMI 25 to 29.9 (74 mm;
P = 0.008), while no significant differences were found
compared to obese patients with BMI ≥30 (88 mm;
P-value not significant.) (Table 1). Baseline levels of
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adiponectin were higher in lean compared to overweight
patients (P = 0.013) and compared to obese patients
(P = 0.003) (Table 2). Leptin levels were lowest in lean
patients and tended to be higher in overweight patients
(P = 0.067) and were highest in obese patients
(P <0.001). Resistin levels did not differ significantly
between groups. Total IGF-1 was higher in lean patients
compared to overweight patients (160.0 vs 113.0 ng/ml,
P = 0.026) and obese patients (160.0 vs 106.5,
P = 0.056), (Table 3). Serum free IGF-1 and IGFB3 did
not differ between the groups.
Fatigue was also related to adipokine levels and IGF-1
levels. Baseline fatigue was negatively correlated with
serum levels of leptin (r = -0.345, P = 0.016, n = 48)
and NGF (r = -0.412, P = 0.037, n = 26) (Table 4). Lep-
tin correlated negatively with total IGF-1 (r = -0.354,
P = 0.020, n = 43) and positively with NPY (r = 0.472,
P = 0.015, n = 26) and NGF. Serum free IGF-1 corre-
lated with total IGF-1 (r = 0.366; P = 0.016; n = 43) and
IGFB3 (r = 0.361; P = 0.016; n = 44) and with NGF
(r = 0.401; P = 0.042; n = 26). In lean patients, baseline
fatigue was negatively associated with resistin levels
(r = -0.694; P = 0.038; n = 9).
FIQ Fatigue was negatively associated with resistin levels
in CSF (r = -0.365, P = 0.073, n = 25) (Table 5). A similar
pattern was seen for CSF levels of adiponectin with nega-
tive correlations to FIQ fatigue (r = -0.444, P = 0.026,
n = 25) and MFIGF (r = -0.508, P = 0.01, n = 25).
Influence of exercise on fatigue
In the group as a whole, FIQ fatigue was decreased after
15 weeks (median -4, interquartile range -15 to 4,
P = 0.024, n = 47), and after 30 weeks both FIQ fatigue
(-2, -7 to 4.5; P = 0.252, n = 44) and MFIGF were
decreased (-2, -4 to -1, P <0.001, n = 44). In lean
patients, FIQ fatigue (-7, 13.5 to 0, P = 0.046) and
MFIGF (-2, -4.2 to 0, P = 0.084) were decreased after 15
weeks (Table 1). After 30 weeks, MFIGF decreased
significantly in lean patients, (-3, -5.5 to -2, P = 0.017),
overweight patients (-2, -3 to 0, P = 0.001) and obese
patients (-3, -4 to -1, P = 0.016), and the direction of
change in FIQ fatigue was the same although not
significant.
Influence of exercise on levels of IGF-1, adipokines and
neuropeptides
As mentioned above, total IGF-1 was highest in lean
patients and lower in overweight and obese patients
(Table 3). After 15 weeks, total IGF-1 was further
increased in lean patients (33 ng/ml, 0 to 51, P = 0.043, n
= 7), but was unchanged in overweight patients (10, -13.5
to 19, P = 0.309, n = 17) and in obese patients (-1, -22 to
4.5, P = 0.255). The change in total IGF-1 differed signifi-
cantly between lean and obese patients (P= 0.010). After
30 weeks, serum free IGF-1 was significantly decreased in
obese patients (-2.1 ng/ml, -4.7 to -0.1, P = 0.017, n = 10)
and in overweight patients (-0.7, -1.6 to 0.6, P = 0.053,
Table 1 Clinical data in lean, overweight and obese patients with fibromyalgia
Lean (group 1) Overweight (group 2) Obese (group 3) Lean vs overweight Lean vs obese










26 32.7 (30.8 to 35.7) 13 <0.001 <0.001




26 15.0 (13.0 to 16.0) 13 0.224 0.393









26 17.0 (14.5 to 20.0) 13 0.061 0.209








26 -8.0 (-20.5 to 2.0)
P = 0.059
13 0.368 0.972





8 -2.0 (-7.0 to 8.8)
P = 0.966
24 -2.5 (-6.8 to 4.5)
P = 0.345
12 0.254 0.473
Change in MFIGF after 15 weeks -2.0 (-4.2 to 0.0)
P = 0.084
8 0.0 (-1.2 to 1.0)
P = 0.515
26 0.0 (-3.5 to 1.0)
P = 0.641
13 0.164 0.336
Change in MFIGF after 30 weeks -3.0
(-5.5 to -2.0)
P = 0.017
8 -2.0 (-3.0 to 0.0)
P = 0.001
24 -3.0 (-4.0 to -1.0)
P = 0.016
12 0.147 0.624
Levels of fatigue (FIQ and MFIGF) at baseline (0 weeks), during training (15 weeks) and after training (30 weeks). Lean patients had BMI 18.5 to 24.9; overweight
patients had BMI 25.0 to 29.9. Obese patients had BMI ≥30.0. Median values and interquartile range are indicated. aMann-Whitney U-test. n, number; BMI, body
mass index; FIQ, Fibromyalgia Impact Questionnaire; MFIGF, Multidimensional Fatigue Inventory subscale of General Fatigue.
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n = 24) but was unchanged in lean FM patients. Resistin
increased in the group as a whole after 30 weeks (944 pg/
ml, -819 to 4299, P = 0.034, n = 41), while adiponectin
and leptin were unchanged after 30 weeks. NPY levels
were increased after 30 weeks (11.1, 0.6 to 33, P = 0.017,
n = 22), this increase was only significant in obese
patients (44.4, 18.3 to 1272, P = 0.043, n = 5). Adiponec-
tin levels were increased in the whole group of FM
patients after 15 weeks (695, -432 to 1891, P = 0.022,
n = 47) but not after 30 weeks.
Changes in fatigue in relation to IGF-1, adipokines and
neuropeptides
Change in MFIGF (ΔMFIGF) after 15 weeks was negatively
correlated with Δtotal IGF-1 (r = -0.329, P = 0.050, n = 36).
In lean patients, Δtotal IGF-1 was correlated with Δresistin
in serum (r = 0.829, P = 0.021, n = 7) after 15 weeks; Δfree
IGF-1 after 15 weeks of exercise correlated positively with
ΔNGF in serum (r = 0.428, P = 0.029, n = 26).
After 30 weeks, Δfree IGF-1 was negatively correlated
with ΔNPY (r = -0.563, P = 0.006) (Table 6). ΔFIQ fatigue
was correlated negatively with ΔNGF (r = -0.463,
P = 0.034, n = 21) and positively with ΔNPY (r = 0.469, P
= 0.032, n = 21). ΔMFIGF correlated negatively with
Δresistin (r = -0.346, P = 0.031, n = 39); this negative cor-
relation was strong in obese patients (r = -0.815,
P = 0.007, n = 9) (Table 7) but was much weaker in lean
and overweight patients. In obese patients, ΔFIQ fatigue
after 30 weeks was negatively correlated with Δfree IGF-1
(r = -0.711, P = 0.032, n = 9) and Δadiponectin
(r = -0.753, P = 0.019) (Table 7).
Type 1 error
Analyses of baseline data, changes in fatigue, levels of
adipokines and IGF levels (Tables 1, 2, 3, and text) com-
prised a total of 121 comparisons and the upper level of
the number of false significant results was 5.10, which
means that five of the significant results might be false.
Correlations at baseline (Tables 4 and 5, and text),
comprised a total of 57 comparisons and the upper level
of the number of false significant results was 2.26,
which means that two significant results might be false.
Table 2 Adipokines in lean, overweight and obese patients
Lean (group 1) Overweight (group 2) Obese (group 3) Comparison of groups
Baseline Δ15
wks


















































































































































































































































































Serum levels of adiponectin, leptin, NPY and resistin at baseline (0 weeks), change (Δ) during training (15 weeks) and change after training (30 weeks). Median
values and interquartile range are indicated. aWilcoxon signed rank test. bMann-Whitney U-test. NPY, neuropeptide Y.
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Table 3 Serum free IGF-1, total IGF-1 and IGFB3 in lean, overweight and obese patients














































































































































































































Levels of serum free IGF-1, total serum IGF-1 and serum IGFB3 at baseline (0 weeks), change (Δ) during training (15 weeks) and change after training (30 weeks).
Median values and interquartile range are indicated. aWilcoxon signed rank test. bMann-Whitney U-test. IGF-1, insulin-like growth factor-1; IGFB3, insulin-like
growth factor-binding protein-3.
Table 4 Fatigue versus adipokines, IGF-1 and neuropeptides





















































































































































































Correlation between baseline fatigue (FIQ and MFIGF), serum free IGF-1, serum levels of total IGF-1, IGFB3, adipokines and neuropeptides. r, Spearman’s
correlation coefficient; P, P-value; n, number; MFIGF, Multidimensional Fatigue Inventory subscale of General Fatigue; FIQ, Fibromyalgia Impact Questionnaire; IGF,
insulin-like growth factor; IGFB3, insulin-like growth factor-binding protein-3; NGF, nerve growth factor.
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Correlations with regard to change (Tables 6 and 7, and
text), comprised a total of 93 comparisons and the
upper level of number of false significant results was
4.21, which means that four significant results might be
false.
Discussion
Fatigue is a debilitating and common health problem
in FM and in many autoimmune rheumatic diseases,
influencing quality of life, work ability and motivation
to exercise. The cause of fatigue is multifactorial and
poorly understood. Suggested causes of chronic fatigue
include central and peripheral neuropeptides and
cytokines, endocrine dysregulation and secondary
effects due to pain, depression and sleep disturbance
[3,18,55,56,67].
Aerobic exercise, together with pharmacological treat-
ment, is one of the cornerstones of treatment for FM
[68], and many patients with FM report lower levels of
fatigue after a lengthy exercise period [63,69]. In this
group of women with FM, the response to aerobic exer-
cise on fatigue was related to levels of BMI. Lean patients
already reported significantly reduced fatigue after 15
weeks of exercise. The response to exercise in overweight
and obese patients was delayed, but a significant reduc-
tion in fatigue was found after six months. An association
Table 5 Correlation between baseline fatigue and cerebrospinal fluid levels of adipokines and neuropeptides
MFIGF Adiponectin CSF Leptin CSF Resistin CSF NPY CSF NGF CSF

































Correlation between baseline fatigue (FIQ and MFIGF) and cerebrospinal fluid levels of adiponectin, leptin, resistin, NPY and NGF. r, Spearman’s correlation
coefficient; P, P-value; n, number; FIQ, Fibromyalgia Impact Questionnaire; MFIGF, Multidimensional Fatigue Inventory subscale of General Fatigue; CSF,
cerebrospinal fluid; NPY, neuropeptide Y; NGF, nerve growth factor.























































































































































































































Correlation after 30 weeks between change (Δ) in fatigue (ΔFIQ and ΔMFIGF) and change in serum free IGF-1, serum levels of IGFB3, adipokines and
neuropeptides. r, Spearman’s correlation coefficient; P, P-value; n, number; FIQ, Fibromyalgia Impact Questionnaire; MFIGF, Multidimensional Fatigue Inventory
subscale of General Fatigue; IGF, insulin-like growth factor; IGFB3, insulin-like growth factor-binding protein-3; NGF, nerve growth factor; NPY, neuropeptide Y.
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between BMI and fatigue in FM has previously been
reported [70], and a high BMI together with inactivity
also increases the risk for development of FM [71]. In
our material, the overweight group reported lower levels
of fatigue than the lean group. Fatigue levels between the
lean and obese groups did not significantly differ.
We used two different instruments to rate fatigue [72].
Both ratings of general fatigue reflect symptom severity,
but somewhat different aspects. The FIQ rates the global
feeling of fatigue, possibly including a feeling of pain,
and the MFIGF estimates fatigue in relation to feeling
fit, tired and rested.
We found evidence of a positive role for total and free
bioactive IGF-1 on fatigue. This is in line with previous
reports that IGF-1 has a protective role in FM
[17-19,73] promoting adaptation and neuroplasticity in
the central nervous system [20,21]. Baseline levels of
resistin in CSF were negatively correlated with fatigue.
The same pattern, although not significant, was seen for
resistin in serum. Increased resistin after 6 months cor-
related with reduced fatigue. Thus, the increase in resis-
tin during exercise appears to improve fatigue, and the
positive effects may be especially important in obese
patients. Resistin represents a potential link between
inflammation and metabolism and can stimulate TLR4
[36] as well as promote IGF-1 receptor signaling [37].
To the best of our knowledge, resistin has not pre-
viously been studied in relation to fatigue.
We also found evidence of a role for adiponectin,
leptin and NPY in the reduced fatigue after exercise.
Serum leptin and cerebrospinal adiponectin were both
associated with low fatigue at baseline, and change in
adiponectin correlated with reduced fatigue. NPY corre-
lated with increased fatigue. Serum leptin is taken up
via the blood-brain barrier and is a central regulator of
energy levels with behavioral effects [43,42,48]. The
arcuate nucleus of the hypothalamus is believed to be
important in mediating these effects [43,74]. Different
peripheral energy signals such as leptin and insulin [74]
were found to activate different but overlapping subpo-
pulations of arcuate NPY neurons. In line with this, the
IGF-1-receptor is expressed in arcuate neurons and glial
cells [75], and IGF-1 receptor activation is important for
neuroplasticity in the arcuate hypothalamus [76]. Simi-
larly, resistin can activate hypothalamic neurons and
induce NPY expression in the hypothalamus [77]. Based
on our findings, the roles of leptin and NPY in fatigue
and the long-term effects of exercise merit further study.
This is an exploratory longitudinal study. Since we
aimed to investigate the interaction of IGF-1 and adipo-
kines in relation to BMI, the study includes many
analyses. Due to multiple analyses, the significance level

















































































































































































































































Correlation after 30 weeks between change (Δ) in fatigue (ΔFIQ and ΔMFIGF) and change in serum free IGF-1, serum levels of IGFB3, adipokines and
neuropeptides in lean patients, overweight and obese patients. r, Spearman’s correlation coefficient; P, P-value; n, number; FIQ, Fibromyalgia Impact
Questionnaire; MFIGF, Multidimensional Fatigue Inventory subscale of General Fatigue; IGF, insulin-like growth factor; IGFB3, insulin-like growth factor-binding
protein-3; NGF, nerve growth factor; NPY, neuropeptide Y.
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should be interpreted with caution, and the upper limit
of the expected number of false sigificant results is pre-
sented in the Results section.
Conclusions
Aerobic exercise reduced fatigue in all FM patients; this
effect was achieved early in lean patients. In overweight
and obese patients the reduction of fatigue was most
pronounced after 6 months. Fatigue in FM patients is
inversely correlated to resistin in serum and CSF, indi-
cating a beneficial role of resistin. The long-term reduc-
tion of fatigue following exercise correlated with
increased levels of resistin. The inverse correlation of
resistin with reduced fatigue was more pronounced in
obese FM patients. Changes in IGF-1 indicate a similar
beneficial role on fatigue in obese patients. The results
also indicate the involvement of leptin, adiponectin and
NPY, although it is not clear how these signals may
interact with each other in chronic fatigue.
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